Related Experiment Videos
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day
M H Davidson1, E A Stein, C A Dujovne
1Chicago Center for Clinical Research, Illinois, USA.
Insights
Higher doses of simvastatin effectively lower LDL cholesterol in patients with coronary artery disease. Increasing simvastatin dosage to 80 and 160 mg/day offers additional lipid-lowering benefits with a low incidence of adverse effects.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Diseases
Background:
- Simvastatin is a potent hydroxymethylglutaryl coenzyme A reductase inhibitor for managing hyperlipidemia.
- Current guidelines recommend low-density lipoprotein (LDL) cholesterol <100 mg/dl for patients with coronary artery disease.
- Maximal simvastatin monotherapy (40 mg/day) may not achieve target LDL levels in all patients.
Purpose of the Study:
- To evaluate the efficacy and safety of higher simvastatin dosages (80 and 160 mg/day) compared to the standard 40 mg/day.
- To assess the impact of increased simvastatin doses on LDL cholesterol and triglyceride levels.
- To determine the incidence of adverse effects associated with higher simvastatin doses.
Main Methods:
- A 26-week, double-blind, 3-period crossover study involving 156 subjects.
- Subjects with LDL cholesterol >160 mg/dl and triglycerides <350 mg/dl were randomized to simvastatin 40, 80, or 160 mg/day.
- Each treatment period lasted 6 weeks with 2-week washout intervals.
Main Results:
- Median LDL cholesterol reductions were 41% (40 mg), 47% (80 mg), and 53% (160 mg).
- Triglyceride reductions were 21% (40 mg), 23% (80 mg), and 33% (160 mg).
- High-density lipoprotein (HDL) cholesterol increased 6-8% across all groups; myopathy and transaminase elevations were infrequent.
Conclusions:
- Simvastatin at 80 and 160 mg/day demonstrates enhanced efficacy in lowering LDL cholesterol and triglycerides.
- Higher doses are associated with a low short-term incidence of adverse effects.
- These findings support further investigation of higher simvastatin dosages for lipid management.
Abstract:
The hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin is the most effective of the currently approved hypolipidemic drugs and has been shown to reduce mortality and coronary morbidity in patients with coronary artery disease. For these patients the United States National Cholesterol Education Program advocates reducing low-density lipoprotein (LDL) cholesterol to <100 mg/dl. However, in some patients this cannot be achieved using monotherapy with simvastatin 40 mg/day, the current maximal recommended dose. To evaluate the effectiveness of extending the dosage range, 156 subjects with LDL cholesterol >160 mg/dl and triglycerides (TG) <350 mg/dl were randomized to simvastatin at doses of 40, 80, and 160 mg/day in a 26 week, double-blind, 3-period, complete block crossover study. Each active treatment period was 6 weeks in duration with intervening 2 week washout periods. Median reductions from baseline in LDL cholesterol were 41%, 47%, and 53% in the 40-, 80-, and 160-mg groups, respectively. The corresponding reductions in plasma TG were 21%, 23%, and 33%. High-density lipoprotein (HDL) cholesterol increased by 6% to 8% in each group. One patient (0.7%) taking 160 mg developed myopathy; 1 patient (0.7%) taking 80 mg, and 3 (2.1%) taking 160 mg had transaminase elevations > 3 times the upper limit of normal. No new or unexpected adverse effects were observed. We conclude that simvastatin at doses of 80 and 160 mg/day provides additional efficacy with a low short-term incidence of adverse effects; our results support the continued investigation of simvastatin at these doses.